Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Gonzales, Milagros ^a   Pepin, Jacques ^a   Frost, Eric H ^a   Carrier, Julie C ^a   Sirard, Stephanie ^a   Fortier, Louis Charles ^a   Valiquette, Louis ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED CLINICAL TRIAL; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG MEGADOSE; DRUG WITHDRAWAL; FECES ANALYSIS; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; CHEMISTRY; CLOSTRIDIUM INFECTION; FECES; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECES; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; VANCOMYCIN;

EID: 78650593791     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-363     Document Type: Article

References (36)

1. Freeman J, Baines SD, Saxton K, Wilcox MH. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007, 60:83-91. 10.1093/jac/dkm113, 17483547.
2. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pepin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472. 514643, 15337727.
3. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084. 10.1016/S0140-6736(05)67420-X, 16182895.
4. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449. 10.1056/NEJMoa051639, 16322602.
5. Saxton K, Baines SD, Freeman J, O'Connor R, Wilcox MH. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 2009, 53:412-420. 10.1128/AAC.00306-08, 2630646, 18710908.
6. Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S, Gerding DN, Vedantam G. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 2010, 192:4904-4911. 10.1128/JB.00445-10, 20675495.
7. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002, 346:334-339. 10.1056/NEJMcp011603, 11821511.
8. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee JT. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983, 2:1043-1046. 10.1016/S0140-6736(83)91036-X, 6138597.
9. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996, 22:813-818.
10. Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2005, CD004610.
11. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995, 44:1-13.
12. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997, 92:739-750.
13. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307. 10.1086/519265, 17599306.
14. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005, 40:1591-1597. 10.1086/430315, 15889355.
15. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989, 86:15-19. 10.1016/0002-9343(89)90223-4, 2910090.
16. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455. 10.1086/651706, 20307191.
17. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009, 15:1067-1079. 10.1111/j.1469-0691.2009.03099.x, 19929973.
18. Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978, 2:226-228. 10.1016/S0140-6736(78)91741-5, 79026.
19. Keighley MR, Burdon DW, Arabi Y, Williams JA, Thompson H, Youngs D, Johnson M, Bentley S, George RH, Mogg GA. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J 1978, 2:1667-1669. 10.1136/bmj.2.6153.1667, 1609009, 367509.
20. Lucas RA, Bowtle WJ, Ryden R. Disposition of vancomycin in healthy volunteers from oral solution and semi-solid matrix capsules. J Clin Pharm Ther 1987, 12:27-31.
21. Baird DR. Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficile. J Antimicrob Chemother 1989, 23:167-169. 10.1093/jac/23.1.167, 2745253.
22. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992, 117:297-302.
23. Lemee L, Dhalluin A, Testelin S, Mattrat MA, Maillard K, Lemeland JF, Pons JL. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 2004, 42:5710-5714. 10.1128/JCM.42.12.5710-5714.2004, 535266, 15583303.
24. Bidet P, Barbut F, Lalande V, Burghoffer B, Petit JC. Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett 1999, 175:261-266. 10.1111/j.1574-6968.1999.tb13629.x, 10386377.
25. Fortier LC, Moineau S. Morphological and genetic diversity of temperate phages in Clostridium difficile. Appl Environ Microbiol 2007, 73:7358-7366. 10.1128/AEM.00582-07, 2168219, 17890338.
26. Wong SS, Woo PC, Luk WK, Yuen KY. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999, 34:1-6. 10.1016/S0732-8893(98)00139-4, 10342100.
27. Freeman J, Stott J, Baines SD, Fawley WN, Wilcox MH. Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 2005, 56:988-989. 10.1093/jac/dki357, 16195254.
28. Aspevall O, Lundberg A, Burman LG, Akerlund T, Svenungsson B. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother 2006, 50:1890-1892. 10.1128/AAC.50.5.1890-1892.2006, 1472208, 16641471.
29. Bourgault AM, Lamothe F, Loo VG, Poirier L. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada. Antimicrob Agents Chemother 2006, 50:3473-3475. 10.1128/AAC.00479-06, 1610058, 17005836.
30. Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJ. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003, 47:2334-2338. 10.1128/AAC.47.7.2334-2338.2003, 161871, 12821492.
31. Finegold SM, John SS, Vu AW, Li CM, Molitoris D, Song Y, Liu C, Wexler HM. In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Anaerobe 2004, 10:205-211. 10.1016/j.anaerobe.2004.04.003, 16701520.
32. Robbins MJ, Marais R, Felmingham D, Ridgway GL, Gruneberg RN. In vitro activity of vancomycin and teicoplanin against anaerobic bacteria. Drugs Exp Clin Res 1987, 13:551-554.
33. Pogue JM, DePestel DD, Kaul DR, Khaled Y, Frame DG. Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. Transpl Infect Dis 2009, 11:467-470. 10.1111/j.1399-3062.2009.00426.x, 19638004.
34. Dudley MN, Quintiliani R, Nightingale CH, Gontarz N. Absorption of vancomycin. Ann Intern Med 1984, 101:144.
35. Matzke GR, Halstenson CE, Olson PL, Collins AJ, Abraham PA. Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis 1987, 9:422-425.
36. Spitzer PG, Eliopoulos GM. Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis. Ann Intern Med 1984, 100:533-534.